Acquired resistances cause many cancer and infectious disease treatments to fail
Acquired resistances cause many cancer and infectious disease treatments to fail due to the resilience of target proteins and reliance on non-highly conserved disease targets.
TAER-TAB™ & ViTRAP
Pinetree Therapeutics has two main technologies TAER-TAB™ (Tumor Associated Essential Receptor Targeting Antibodies) and ViTRAP (Virus Targeting Recombinant Agent) which promote disease-specific target protein degradation and allow for targeting of highly-conserved disease targets.
Around $27B market
Pinetree Therapeutics is targeting multiple large markets, such as the non-small cell lung cancer market which has been estimated to be ~$27B in 2022.
“Our approaches range from the degradation of drug resistant-oncogenic and immuno-oncology receptors, in situ cancer vaccination, to even anti-viral infection therapeutics, which is one of a kind and has never been tried before.”
Ho-Juhn Song (Founder)
Get in touch
Contact us for more information about how we can help you invest in healthcare, biotech, climate tech, or advanced systems.